Drugs / ACAM2000
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00053482 | Jan → Apr 2003 | smallpox | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 2 | NCT00053495 | Jan → Jun 2003 | smallpox | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01913353 | Mar 2015 → Mar 2017 | — | Bavarian Nordic | Completed | No outcome recorded |
| Phase 3 | NCT01158157 | Sep 2010 → Feb 2012 | vaccinia | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02443623 | Sep 2015 → Jul 2021 | vaccinia | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACAM2000 | “one dose of the established replicating-vaccinia vaccine ACAM2000” PMID 31722150 ↗ Nov 2019 |
| Modality | Vaccine | “ACAM2000 smallpox vaccine” NCT00053482 ↗ |
| Route | Other | “Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.” NCT01158157 ↗ |